| 17.34 Data as of Jun 18 |  +0.10 / +0.58%Today’s Change | 13.87 Today|||52-Week Range 29.37 | -6.47% Year-to-Date |
| Identifying the Biggest Gem in Antares's Pipeline Jun 13 / MotleyFool.com |
| Previous close | 17.24 |
| Today’s open | 17.29 |
| Day’s range | 16.95 - 17.39 |
| Volume | 588,146 |
| Average volume (3 months) | 809,189 |
| Market cap | $850.0M |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -102.66% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +49.55% |
| P/E ratio | 10.8 |
| Price/Sales | 2.29 |
| Price/Book | 4.25 |
| Today’s change | Today’s % change | |
|---|---|---|
| NBIXNeurocrine Bioscienc... | -0.02 | -0.16% |
| INFIInfinity Pharmaceuti... | +2.29 | +13.34% |
| ACHNAchillion Pharmaceut... | +0.08 | +1.01% |
| USNAUSANA Health Science... | +1.30 | +1.77% |
| Next reporting date | July 30, 2013 |
| EPS forecast (this quarter) | -$0.00 |
| Annual revenue (last year) | $395.3M |
| Annual profit (last year) | $85.9M |
| Net profit margin | 21.74% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Adrian Adams |
Chief Financial Officer & Head-Investor Relations James E. Fickenscher, CPA |
Corporate headquarters Chesterbrook, Pennsylvania |
.
